{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T04:20:10Z","timestamp":1746591610709,"version":"3.40.5"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:p>The systemic amyloidoses are a broad spectrum of diseases that result from misfolding of proteins that aggregate into amyloid fibrils. In cardiac amyloidosis, amyloid fibrils accumulate in the interstitial space between cardiac myocytes causing cellular injury and impairing compliance. Current data suggest that cardiac amyloidosis is more common than previously thought. Advances in cardiac imaging, diagnostic strategies, and therapies have improved the recognition and treatment of cardiac amyloidosis. A position statement for the diagnosis and treatment of cardiac amyloidosis has been published in 2021 by the European Society of Cardiology and an expert consensus decision pathway was published in 2023 by the American College of Cardiology. These are excellent documents but quite lengthy and complex. For this reason, our team developed a novel and simple pathway to help health care providers diagnose and treat patients with cardiac amyloidosis. Our pathway starts with a section titled \u201csuspicion\u201d in which we provide simple clues or \u201cred flags\u201d that are associated with the cardiac amyloidosis phenotype. It is followed by a section titled \u201cdiagnosis,\u201d where we present in a simplified 2\u2009\u00d7\u20092 format the laboratory and imaging tests that must be performed for an accurate diagnosis. In the section titled \u201ctreatment,\u201d we describe the 4 pillars in the management of patients with cardiac amyloidosis, which includes the following: heart failure treatments, management of arrhythmias, treatment of significant aortic stenosis, and appropriate selection of disease modifying therapies. Our algorithm ends with our simplified recommendation for follow-up.<\/jats:p>","DOI":"10.1097\/hpc.0000000000000331","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T16:07:43Z","timestamp":1701101263000},"page":"114-119","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Pathway for the Diagnosis and Management of Cardiac Amyloidosis"],"prefix":"10.1097","volume":"22","author":[{"given":"Eyal","family":"Herzog","sequence":"first","affiliation":[{"name":"Department of Cardiology, Hadassah Medical Center, Hebrew University of Jerusalem, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Leibowitz","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hadassah Medical Center, Hebrew University of Jerusalem, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moshe E.","family":"Gatt","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hadassah Medical Center, Hebrew University of Jerusalem, Israel."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tali","family":"Koren","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hadassah Medical Center, Hebrew University of Jerusalem, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur","family":"Pollak","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hadassah Medical Center, Hebrew University of Jerusalem, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,8,25]]},"reference":[{"key":"R1-20250506","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases.","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"key":"R2-20250506","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology solution set oversight committee.","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"R3-20250506","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines.","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"R4-20250506","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jchf.2021.06.007","article-title":"Spironolactone in patients with an echocardiographic HFpEF phenotype suggestive of cardiac amyloidosis: results from TOPCAT.","volume":"9","author":"Sperry","year":"2021","journal-title":"JACC Heart Fail"},{"key":"R5-20250506","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction.","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"R6-20250506","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacep.2020.01.004","article-title":"Management of arrhythmias in cardiac amyloidosis.","volume":"6","author":"Giancaterino","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"key":"R7-20250506","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jacc.2020.11.006","article-title":"Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis.","volume":"77","author":"Nitsche","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"R8-20250506","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy.","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"R9-20250506","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis.","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"R10-20250506","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis.","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"}],"container-title":["Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HPC.0000000000000331","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T19:02:31Z","timestamp":1746558151000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/HPC.0000000000000331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,25]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/hpc.0000000000000331","relation":{},"ISSN":["1535-2811"],"issn-type":[{"type":"electronic","value":"1535-2811"}],"subject":[],"published":{"date-parts":[[2023,8,25]]}}}